denkapparat Operations GmbH Buys New Stake in DaVita Inc. (NYSE:DVA)

denkapparat Operations GmbH purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,758 shares of the company’s stock, valued at approximately $263,000.

Other institutional investors also recently added to or reduced their stakes in the company. Amundi grew its position in DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after acquiring an additional 240,126 shares during the period. FMR LLC grew its holdings in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock worth $24,301,000 after purchasing an additional 116,758 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in DaVita in the fourth quarter valued at about $9,371,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on DVA shares. StockNews.com cut shares of DaVita from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Finally, Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Down 1.5 %

DaVita stock opened at $150.29 on Friday. The company has a 50 day moving average of $157.39 and a 200-day moving average of $157.50. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The stock has a market capitalization of $12.02 billion, a PE ratio of 13.99, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.